Table 5

Cardioversion studies

AuthorYearStudy designPatients (n)ArrhythmiasAtrial flutter (%)AC treatmentPostcardioversion range of follow-up (weeks)*Embolic eventsEmbolic Incidence
BeforeAfter
Morris et al111964Prospective70Atrial flutter, AF7 (10)44–363
AC+: 0
Jensen et al121965Prospective50Atrial flutter, AF7 (14)2212–6800
Wikland et al131967Prospective74Atrial flutter, AF8 (11)7448–144(1)0 (1.4) %
Bjerkelund and Orning141969Prospective437Atrial flutter, AF, AT228228113
AC+: 2
AC%: 11
2.9
0.9†
5.3‡
Arnold et al151992Retrospective428Atrial flutter, AF122 (28)322–600
Chalasani et al161996Retrospective85Atrial flutter85 (100)100–100
Lanzarotti and Olshansky171997Retrospective100Atrial flutter, AF (6)100 (100)5413 (6)§
AC+: 0
13 (6)%
Crijns et al181997Prospective50Atrial flutter50 (100)504–33600
Bertaglia et al192000Prospective64Atrial flutter64 (100)0400
Elhendy et al¶,**202001Retrospective493Atrial flutter, AF (227)493 (100)4152810–13
AC+: 0
0.5%
Gallagher et al232002Retrospective1950Atrial flutter, AF, AT699†† (36)(150)3–450.7%
Stiell et al212010Prospective660Atrial flutter, AF32 (5)11100
Scheuermeyer et al222011Retrospective122Atrial flutter, AF (49)122 (100)395200
Yadlapati et al242014Retrospective53Atrial flutter, AF10 (19)1010200
  • *If no range is provided, the study entailed follow-up for the reported duration of weeks.

  • †AC group.

  • ‡Non-AC group.

  • §Expected to be associated with atrial flutter.

  • ¶Also reported table 4.

  • **Results given by numbers of procedures and divergent information.

  • ††Atrial flutter combined with unspecific AT and—, no information.

  • AC, anticoagulant treatment; AF, atrial fibrillation; AT, atrial tachycardia.